Skip to content

Virtual Reality-assisted training for Chronic Pain Rehabilitation: The VIREP proof-of-concept study

Virtual Reality-assisted training for Chronic Pain Rehabilitation: The VIREP proof-of-concept study - VIREP study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON46589
Enrollment
15
Registered
2017-11-23
Start date
2018-02-09
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic pain chronic pain

Interventions

The VIREP system has two main components (1) an immersive virtual reality training environment for rehabilitation of chronic pain installed in a computer in a training room of Roessingh, and (2) an

Sponsors

Roessingh Research and Development
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - * 18 years old - diagnosis of chronic pain, included for rehabilitation programme - occupational therapy at Roessingh Rehabilitation Centre - Able to understand and read the Dutch language

Exclusion criteria

Exclusion criteria: - Patients with migraine or epilepsy - Patients with disturbances of equilibrium - Pregnant women - Patients with anxiety disorders, posttraumatic stress syndrome or heart disease, upon rehabilitation physician and occupational therapist*s assessment. - Impaired hand function or other disorders causing inability to use VIREP - Visual impairment

Design outcomes

Primary

MeasureTime frame
The primary study outcomes are perception of gameplay components, experience of the VR environment, acceptance and (clinical) added value.

Secondary

MeasureTime frame
The secondary study outcomes are (1) Contribution of gameplay elements to experience, (2) Contribution of gameplay elements to added value, (3) Contribution of experience to added value, and (4) implementation strategy.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)